In the present set of experiments, GSPE showed a significant anti-hyperalgesic and anti-nociceptive effect in rats.

No abstract

No abstract

Background: Although breast cancer is extremely uncommon during childhood and adolescence, breast concerns and problems among females of this age group are a relatively common occurrence. Objective: The study is conducted to evaluate spectrum of lesions of breast in patients presenting with breast lump and evaluate role of FNAC in lesions of breast. Methods: In present study, fine needle aspiration cytology (FNAC) was done on hundred (100) female patients less than 30 years of age and these were later on operated and histopathology specimens were available for correlation. Results: Out of 100 patients 93% were benign and 7% were malignant. Fibroadenoma was most common present in 63% cases, fibrocystic disease in 11%, phyllodes tumor in 2 % cases, 2% of atypical cases, 1% as papilloma, 1% as mastitis, 7% as malignant. The sensitivity of FNAC was 85.7% specificity was 100%, accuracy was 99%. Conclusion: It was concluded from the present study that expertise of FNAC has reached high accurate levels, FNAC report can be of great value in young females presenting with breast lump.

T-cell prolymphocytic leukemia is a rare and unusual malignancy characterized by the proliferation of small-to mediumsized prolymphocytes of postthymic origin with distinctive, morphologic, immunophenotypic, and cytogenetic features. Involvement of the peripheral blood, bone marrow, lymph nodes, liver, spleen, and skin can occur. The clinical course is typically very aggressive with poor response to conventional chemotherapy and short survival rates, and the only potential long-term curative treatment is hematopoietic stem cell transplantation. We report the case of a man with de novo T-cell prolymphocytic leukemia and discuss the distinctive clinical, morphologic, immunophenotypic, and cytogenetic features of this entity. Prolymphocytic leukemia (PLL) is a rare lymphocytic disorder characterized by marked lymphocytosis and splenomegaly and represents only 2% of all mature lymphocytic leukemias in adults over the age of 30. PLL is clearly defined into subtypes as B-cell prolymphocytic leukemia (B-PLL) and T-cell prolymphocytic leukemia (T-PLL), with T-PLL representing approximately 20% of the cases (1). While these subtypes have their similarities, T-cell and B-cell PLL are two distinct diseases with different clinical and laboratory features. T-PLL is more rare and more rapidly progressive and aggressive than B-PLL.